Advisory Board on potential import substitution of follitropin alfa preparations in IVF cycles

Abstract

On July 17, 2021, Advisory Board with the participation of more than 60 leading reproductive specialists and healthcare executives was held. The primary task was to discuss the real world data on the first Russian biosimilar follitropin alfa and the possibilities of import substitution of follitropin alfa drugs. The information about drug development stages, experience of usage in ovarian stimulation for artificial insemination and assisted reproductive technologies (ART), the results of the largest Russian study in reproduction "FОLLITROPIN" (2020), where biosimilar recombinant human follicle stimulating hormone (FSH) was studied in 5484 IVF cycles in real clinical practice, experience of drug use in leading ART medical centers have been provided in research reports. After discussion the Advisory Board Resolution has been developed.

Keywords

• follitropin alfa
• biosimilar
• follicle stimulating hormone
• fsh
• primapur®
• import substitution
• real clinical practice
• assisted reproductive technologies
• assisted reproductive technologies
• art